Exclusive Sales Start from January
[Asia Economy Reporter Myunghwan Lee] Boryung announced on the 31st that it has signed an exclusive domestic sales contract for 'Taxol' (generic name paclitaxel) with the German pharmaceutical company CephlaPharm. Boryung has also begun full-scale sales and marketing activities this month.
Taxol is the original drug containing paclitaxel developed by the global pharmaceutical company Bristol-Myers Squibb (BMS). It is an alkaloid-type anticancer drug indicated for various cancers such as ovarian cancer, breast cancer, lung cancer, and stomach cancer. As a mitotic inhibitor, Taxol blocks cell division and induces cancer cell death. Currently, the sales rights of Taxol are held by the German pharmaceutical company CephlaPharm. Through this contract with CephlaPharm, Boryung has obtained exclusive sales rights and also acquired the domestic approval rights for Taxol from Korea BMS Pharmaceutical, the previous domestic license holder.
Boryung's sales of Taxol mark a return after seven years since 2015. Boryung had previously conducted co-promotion of Taxol with BMS from 2008 to 2015. Since 2016, Boryung started co-promotion of paclitaxel generics and achieved the top position in paclitaxel formulations within about a year.
Boryung announced plans to make Taxol the market leader in paclitaxel market share by leveraging its specialized oncology organization and sales and marketing competitiveness. Boryung is the only domestic company with a dedicated oncology team. Based on its portfolio ranging from synthetic drugs to biosimilars and anticancer adjuvants, it holds the number one market share in the anticancer drug market among Korean pharmaceutical companies.
Boryung plans to expand Taxol prescriptions by conducting specialized academic marketing for major indications and creating synergy effects with its existing anticancer drug portfolio. According to data from IQVIA, a pharmaceutical market research firm, Taxol's prescription amount was 8.1 billion KRW over the past year (October 2021 to September 2022), ranking second in the paclitaxel ingredient market.
Kim Young-seok, head of the Onco division, stated, "Taxol is an original paclitaxel product whose efficacy and safety have been proven through long-term domestic and international clinical trials. We will focus on expanding Taxol prescriptions based on its excellent product quality and Boryung's specialized oncology capabilities."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
